MRSN · As filed with the SEC
Mersana Therapeutics balance sheet, by quarter
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets · USD thousands
| USD thousands | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 56,391 | 76,972 | 102,287 | 107,750 |
| Short-term marketable securities | 0 | 0 | 0 | 26,870 |
| Accounts receivable | 168 | 266 | — | — |
| Prepaid expenses and other current assets | 3,429 | 2,903 | 3,901 | 2,284 |
| Total current assets | 59,988 | 80,141 | 106,188 | 136,904 |
| Property and equipment, net | 163 | 1,037 | 1,887 | 2,203 |
| Operating lease right-of-use assets | 2,035 | 2,895 | 3,739 | 4,578 |
| Other assets, noncurrent | 500 | 500 | 657 | 978 |
| Total assets | 62,686 | 84,573 | 112,471 | 144,663 |
| Liabilities and stockholders’ deficit | ||||
| Current liabilities: | ||||
| Accounts payable | 2,393 | 2,923 | 4,374 | 4,330 |
| Accrued expenses | 14,813 | 15,184 | 12,974 | 18,964 |
| Deferred revenue | 23,770 | 20,183 | 23,715 | 22,168 |
| Operating lease liabilities | 2,293 | 3,270 | 3,961 | 3,856 |
| Short-term debt, net | 0 | 17,351 | 12,500 | 12,500 |
| Other current liabilities | 0 | 427 | 637 | 640 |
| Total current liabilities | 43,269 | 59,338 | 58,161 | 62,458 |
| Operating lease liabilities, noncurrent | 0 | 0 | 262 | 1,292 |
| Long-term debt, net | 0 | 0 | 7,901 | 10,950 |
| Deferred revenue, noncurrent | 78,954 | 78,381 | 77,015 | 79,464 |
| Other liabilities, noncurrent | 0 | 0 | 0 | 8 |
| Total liabilities | 122,223 | 137,719 | 143,339 | 154,172 |
| Stockholders' deficit: | ||||
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | 0 |
| Common stock, $0.0001 par value; 350,000,000 shares authorized; 4,998,500 and 4,626,010 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 0 | 0 | 12 | 12 |
| Additional paid-in capital | 891,980 | 890,826 | 888,796 | 886,022 |
| Accumulated other comprehensive income | 0 | 0 | 0 | 10 |
| Accumulated deficit | (951,517) | (943,972) | (919,676) | (895,553) |
| Total stockholders’ deficit | (59,537) | (53,146) | (30,868) | (9,509) |
| Total liabilities and stockholders’ deficit | 62,686 | 84,573 | 112,471 | 144,663 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.